The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monthly Archives: June 2011

Monday Biotech Deal Review: June 27, 2011

Welcome to your Monday Biotech Deal Review for June 27, 2011.  There were a number of financings announced and closed in the previous week, as well as some M&A activity involving Cynapsus acquiring the shares of Adagio Pharmaceuticals.  Read on to learn more. 

Friday Science Review: June 24, 2011

New Drug Targets in the Ubiquitin-Proteasome System? Mount Sinai Hospital ♦ University of Montreal ♦ Structural Genomics Consortium ♦ Celgene Signal Research Division ♦ Wellcome Trust Centre for Cell Biology ♦ University of Toronto Published in Cell, June 24, 2011 Proteins within the ubiquitin-proteasome system are responsible for modulating the stability and cellular localizations of [...]

Valuation and other biotech mysteries – Part 5: More strategy and structure for Phase 3 clinical trials

[Ed. This is the fifth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] In the previous case study, we looked back at Theratechnologies and theFDA approval of EGRIFTA™ (tesamorelin for injection). [...]

Canadian Drug Pricing and Reimbursement Conference Report

Earlier this week, the Canadian Institute held its 5th annual Drug Pricing and Reimbursement Conference in Toronto. The conference highlighted a number of key issues including market access for pharmaceutical companies, Federal and Provincial regulatory and reimbursement policies, and global trends that may affect Canada’s pharmaceutical landscape. Attendees included both innovative and generic drug manufacturers, public [...]

Monday Biotech Deal Review: June 20, 2011

Welcome to your Monday Biotech Deal Review for June 20, 2011.  Notable transactions from the previous week included the public offering of units by Resverlogix, as well as investments by HTX and the Business Development Bank of Canada in each of Milestone Pharmaceuticals  and Profound Medical Inc.  Read on to learn more.

Friday Science Review: June 17, 2011

New Players in Interleukin-17 Response to Bacterial Pathogens University of Toronto ♦ St. Michael’s Hospital ♦ Published in Nature Medicine, June 12, 2011 Interleukin-17 (IL-17) is a well established chemical messenger that modulates antimicrobial immune response in the stomach and intestine in the presence of various bacterial pathogens, including Pseudomonas, Helicobacter,  Citrobacter, and Salmonella; this [...]

Preview — BIO and Scientific American’s Regional Bio-Innovation Scorecard

The BIO 2011 conference is just around the corner, and Washington DC prepares for some 15,000 delegates from 65 different countries to descend upon its limits, which means it’s almost time for this year’s Worldview Regional Bio-Innovation Scorecard. This morning, the Biotechnology Industry Organization (BIO) hosted a press conference in DC to provide some highlights [...]

Monday Biotech Deal Review: June 13, 2011

Welcome to your Monday Biotech Deal Review for June 13, 2011.  Notable stories include the completion of GeneNews’ early warrant exercise program and debenture conversion opportunity, resulting in gross proceeds of nearly $3M to the Company.  As well, Somaxon and Paladin Labs have teamed up for the commercialization of Selinor in Canada, South America and [...]

Friday Science Review: June 10, 2011

Silence is Golden University of British Columbia ♦ BC Cancer Agency ♦ Institute for Virus Research ♦ Kyoto University Published in Cell Stem Cell, June 3, 2011 Researchers analyzing the genome wide repression of genes and other repetitive elements, like endogenous retroviruses (ERVs), have come upon some findings that illustrate how epigenetic silencing occurs in [...]

Pharma / Biotech R&D Budgets – A Proposal For Measuring Performance

During the BioFinance 2011 conference held in Toronto last week, one presenter showed a slide that outlined the number of new chemical entities (NCEs) approved by the FDA over a number of years. Since this slide was used in the context of the increase in global industry R&D budgets, it was meant to show that [...]

Monday Biotech Deal Review: June 6, 2011

Welcome to your Monday Biotech Deal Review for June 6, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP summer student Steven Zuccarelli who, before entering law school at Osgoode Hall Law School, obtained his B.Sc and M.Sc at McMaster University in Biochemistry and Health Sciences, respectively, where he was [...]

Valuation and other biotech mysteries – Part 4: Strategy and structure for Phase 3 clinical trials

[Ed. This is the fourth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] Very few independent Canadian biotech companies have successfully completed the development of a novel drug – so my [...]

Friday Science Review: June 3, 2011

Horizontal Gene Transfer: Bacterial Adaptation McGill University ♦ Fudan University, China ♦ Published in PLoS ONE, May 20, 2011 The bacterium S. aureus can cause a host of problems in humans, companion animals, and cattle. Its ability to adapt and circumvent the effects of antibiotics allow it to persist, while virulence factors, acquired via horizontal [...]

Valuation and other biotech mysteries – Part 3: What are you valuing?

[Ed. This is the third part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] Most likely you will be valuing a company, a product or a technology. The valuation of the stream [...]

Follow

Get every new post delivered to your Inbox.

Join 76 other followers